SI1429800T1 - Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne skleroze - Google Patents
Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne sklerozeInfo
- Publication number
- SI1429800T1 SI1429800T1 SI200230800T SI200230800T SI1429800T1 SI 1429800 T1 SI1429800 T1 SI 1429800T1 SI 200230800 T SI200230800 T SI 200230800T SI 200230800 T SI200230800 T SI 200230800T SI 1429800 T1 SI1429800 T1 SI 1429800T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cop
- vaccine
- lateral sclerosis
- amyotrophic lateral
- treatment
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- 208000026072 Motor neurone disease Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33613901P | 2001-12-06 | 2001-12-06 | |
| EP02788511A EP1429800B1 (en) | 2001-12-06 | 2002-12-05 | Vaccine and use thereof for treatment of amyotrophic lateral sclerosis |
| PCT/IL2002/000979 WO2003047500A2 (en) | 2001-12-06 | 2002-12-05 | Vaccine and method for treatment of motor neurone diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1429800T1 true SI1429800T1 (sl) | 2009-08-31 |
Family
ID=23314742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230800T SI1429800T1 (sl) | 2001-12-06 | 2002-12-05 | Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne skleroze |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7351686B2 (enExample) |
| EP (1) | EP1429800B1 (enExample) |
| JP (1) | JP4542339B2 (enExample) |
| KR (1) | KR20040081431A (enExample) |
| CN (2) | CN1617736A (enExample) |
| AT (1) | ATE422362T1 (enExample) |
| AU (1) | AU2002353486B2 (enExample) |
| CA (1) | CA2469092C (enExample) |
| CY (1) | CY1109044T1 (enExample) |
| DE (1) | DE60231131D1 (enExample) |
| DK (1) | DK1429800T3 (enExample) |
| ES (1) | ES2322566T3 (enExample) |
| HU (1) | HU228207B1 (enExample) |
| IL (1) | IL160105A0 (enExample) |
| IS (1) | IS2670B (enExample) |
| MX (1) | MXPA04005537A (enExample) |
| NO (1) | NO336231B1 (enExample) |
| NZ (1) | NZ533356A (enExample) |
| PL (1) | PL205469B1 (enExample) |
| PT (1) | PT1429800E (enExample) |
| RU (1) | RU2303996C2 (enExample) |
| SI (1) | SI1429800T1 (enExample) |
| WO (1) | WO2003047500A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399740B2 (en) | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
| WO2004060265A2 (en) * | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| DK1701730T3 (da) | 2003-12-09 | 2013-11-25 | Yeda Res & Dev | Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| CA2565819A1 (en) * | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| JP5241012B2 (ja) * | 2005-07-15 | 2013-07-17 | ノバルティス アーゲー | Ｐａｍｐｓ、病原体関連分子パターン |
| CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| US9861686B2 (en) * | 2011-12-05 | 2018-01-09 | Ben-Gurion University Of The Negev Research & Development Authority | Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS) |
| KR20140145173A (ko) * | 2012-03-26 | 2014-12-22 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커 |
| EP2892353A4 (en) | 2012-09-10 | 2016-10-26 | Yeda Res & Dev | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3849650A (en) | 1973-03-29 | 1974-11-19 | Picker Corp | Automatic x-ray inspection system |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| SE505316C2 (sv) * | 1995-10-17 | 1997-08-04 | Kenneth G Haglid | Användning av proteinet S-100b för framställning av läkemedel för nervceller |
| RU2211697C2 (ru) * | 1996-09-27 | 2003-09-10 | Гилфорд Фармасьютикалз Инк. | Способ лечения глутаматных расстройств |
| JP2002503658A (ja) * | 1998-02-13 | 2002-02-05 | オートイミューン インク | ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療 |
| US20030108528A1 (en) | 1998-05-19 | 2003-06-12 | Michal Eisenbach-Schwartz | Activated t-cells, nervous system-specific antigens and their uses |
| US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| WO1999060021A2 (en) | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| EP1039929A1 (en) | 1998-07-21 | 2000-10-04 | YEDA RESEARCH AND DEVELOPMENT Co. Ltd. | Activated t-cells and their uses |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| RU2155063C1 (ru) * | 1999-10-20 | 2000-08-27 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения |
| HK1054507B (zh) * | 2000-01-20 | 2008-10-31 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US6835711B2 (en) * | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
-
2002
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 EP EP02788511A patent/EP1429800B1/en not_active Expired - Lifetime
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko not_active Ceased
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en not_active Ceased
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
-
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
-
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1429800E (pt) | Vacina e sua utilização para tratamento de esclerose lateral amiotrófica | |
| AU6185398A (en) | Charged lipids and uses for the same | |
| AU6762794A (en) | A coagulation factor viii formulation | |
| PL312219A1 (en) | Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids | |
| MY129566A (en) | A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance | |
| WO2002100390A3 (en) | Improved method of treating the syndrome of coronary heart disease risk factors in humans | |
| PL399138A1 (pl) | Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego | |
| CA2299361A1 (en) | Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis | |
| MXPA04000024A (es) | Metodos para inducir una respuesta inmunologica citotoxica y composiciones de adenovirus simio recombinante utiles en los mismos. | |
| PT1471892E (pt) | Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma | |
| IL108285A0 (en) | Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes | |
| NZ516477A (en) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| MXPA02005563A (es) | Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. | |
| GR3024157T3 (en) | Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy. | |
| YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
| CA2414586A1 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
| MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
| NZ505538A (en) | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma | |
| WO2003026570A3 (en) | Reduced toxicity cisplatin formulations and methods for using the same | |
| EP0974360A3 (en) | Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms | |
| SE9902674D0 (sv) | New composition | |
| SE9902673D0 (sv) | New composition |